6 results about "Cell based assays" patented technology

In the field of cell-based assays, i.e. cellular assays, there is a need for improved cell culture retaining inserts and cell culture retaining insert assemblies. A cell culture retaining insert (10; 70; 90; 100), for retaining a three-dimensional biological sample in a cell culture vessel (102; 132), comprises an insert body (12; 104) that has a positioning formation (16) to in-use locate the cell culture retaining insert (10; 70; 90; 100) relative to a cell culture vessel (102; 132). The insert body (12; 104) also has a retention element receiving formation (20). The cell culture retaining insert (10; 70; 90; 100) additionally includes a retention element (30; 60; 72; 92; 114) which is movably coupled with the receiving formation (20) of the insert body (12;104), whereby a distal retention end (32) of the retention element (30; 60; 72; 92; 114) is freely movable away from and towards the insert body (12; 104), and whereby in-use the weight of the retention element (30; 60; 72; 92; 114) less a buoyant force equal to the weight of any fluid the retention element (30; 60; 72; 92; 114) displaces gives rise to the retention end (32) exerting a retention force on one or more said biological samples.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The method as disclosed herein utilizes a high throughput screening assay (GigaAssay) to produce a comprehensive mutation effect on gene activity (MEGA)-mutation activity profile (Map). The methods as disclosed herein can be used to assess the mutational effect for any gene, under any condition (e.g., drug treatment) with any assay in mammalian cells in culture. Thus, the methods provided herein can be utilized to discover and screen dominant negative variants, and provide a reliable solution to the problem of identifying unique pharmacologically active variants of proteins. Furthermore, the method provided herein can be integrated to cell-based assays to investigate disease pathology and test potential drugs.

Disclosed is a Designer Receptor Exclusively Activated by Designer Drugs (DREADD), and an amino acid sequence for determining coupling or no coupling between G-protein and G-protein coupled receptor (GPCR) mediated by a GPCR ligand in a cell based assay.

The present invention provides methods for using waste effluent biofluids in cell culture assays as all or part of the cell culture microenvironment. Methods of the invention contemplate that biofluids typically regarded as waste may be used in cell-based assays to achieve a cell culture microenvironment that provides a novel understanding of cellular response.

Serotype-specific cell based assays for the characterization of Clostridia botulinum neurotoxins and genetically modified cells utilized in such assays are described. Such assays and genetically modified cells can discriminate between different serotypes of clostridium neurotoxins having the same SNARE protein substrate specificity, despite a lack of such discrimination in the parental cell line. This discrimination is achieved without the use of serotype-specific neutralizing antibodies and without the use of competing heavy chains derived from a Clostridia botulinum neurotoxin.